Cannabis rescheduling update
Cannabis remains a Schedule I drug under the Controlled Substances Act. The DEA published a proposed rule in May 2024 to move marijuana to Schedule III after a scientific review by the Department of Health and Human Services. That rule is not final. The proposal moved into administrative hearings, and no change applies to consumers, patients, or CBD sellers until a final rule is signed and takes effect.
New Updates on Cannabis Rescheduling: What You Need to Know
That is the short answer. The sections below cover what the proposal actually does, where it sits in the process, and what it changes for hemp CBD products.
What the Schedule III proposal covers
The proposed rule addresses marijuana as federal drug law defines it, which means cannabis with meaningful THC content. Schedule III is the tier for drugs with accepted medical use and moderate to low abuse potential, such as ketamine and testosterone. Placement there would not make cannabis a legal consumer product. It would change the registration, research, and tax rules that apply to businesses handling it.
Cannabis Rescheduling Latest Updates: Guide for CBD Users
Where the process stands
- HHS completed a scientific review in August 2023 and recommended Schedule III controls.
- DEA published a proposed rule in the Federal Register in May 2024.
- DEA opened a public comment period, which closed in July 2024.
- DEA referred the matter to an administrative law judge for a hearing.
- The judge takes testimony from supporters and opponents, then issues a recommendation.
- The DEA Administrator signs or declines a final rule.
- The final rule publishes in the Federal Register with an effective date.
What rescheduling would not do
- It would not legalize cannabis for recreational use under federal law.
- It would not override state licensing, possession limits, or retail rules.
- It would not settle the FDA question on CBD in foods and supplements.
- It would not move hemp-derived CBD, which already sits outside the CSA definition of marijuana.
What it means for CBD products
Hemp CBD sits outside this rulemaking. The 2018 Farm Bill removed hemp and hemp-derived extracts from the CSA definition of marijuana, so a Schedule III listing for marijuana would not shift hemp CBD's legal status. The limits that matter for CBD buyers come from other places: the FDA has not approved CBD as a food additive or dietary supplement ingredient, and state health departments set their own rules on labeling, potency, and testing.
In practice, the rescheduling debate changes little for a CBD store or a CBD buyer. The useful signal stays on the product side: a certificate of analysis from an accredited lab, a full cannabinoid panel, and a batch number that matches the COA.
How to check the status yourself
- Search the Federal Register for the marijuana rescheduling docket and open the most recent document.
- Read the action line at the top of that document to identify a proposed rule, a hearing notice, or a final rule.
- Check the effective date field; a rule without one has not taken effect.
- Compare the docket to DEA press releases before repeating any claim about a change in the law.